Displaying drugs 6726 - 6750 of 8039 in total
SYNB1353
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion...
Investigational
Matched Description: … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered ... A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of …
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
Matched Description: … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. ... It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Matched Description: … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial ... In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Description: … novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional …
Amperozide
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia …
ADL5859
ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
Investigational
Matched Description: … Delta receptor agonists are thought to offer benefits over other approaches to the management of pain …
Vatreptacog alfa
Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
Investigational
Matched Description: … Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia …
Evogliptin
Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment …
5-fluoro-2'-deoxycytidine
5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
Investigational
Matched Description: … 5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms …
Mavoglurant
Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Investigational
Matched Description: … Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant …
Avadomide
Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).
Investigational
Matched Description: … Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, …
Marzeptacog alfa (activated)
Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
Investigational
Matched Description: … investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of …
Elgemtumab
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of …
Bisphosphocin Nu-3
Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Sepofarsen
Sepofarsen is under investigation in clinical trial NCT03913143 (A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)).
Investigational
Matched Description: … trial NCT03913143 (A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of …
Tafolecimab
Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia).
Investigational
Matched Description: … Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of …
AB-201
AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
Investigational
Matched Description: … [L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric …
EDIT-301
EDIT-301 is an investigational cell therapy consisting of autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the gamma globin gene (HBG1 and HBG2).
Investigational
Matched Description: … EDIT-301 is an investigational cell therapy consisting of autologous CD34+ hematopoietic stem and progenitor …
D-1,4-dithiothreitol
A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Experimental
Matched Description: … A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH ( …
Sphingosine
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. …
N-acetyl-alpha-neuraminic acid
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Experimental
Matched Description: … An N-acyl derivative of neuraminic acid. …
Displaying drugs 6726 - 6750 of 8039 in total